問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taipei Medical University Hospital (在職)

Division of Rheumatology

Division of General Internal Medicine

Division of Nephrology

更新時間：2023-09-19

林子閔Lin, Tzn-Min
  • Principal Investigator
  • Clinical Trial Experience (year) -13 years -4 個月

Recruiting Trial

13Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

林子閔

List

30Cases

2026-05-31 - 2030-06-30

Phase III

Not yet recruiting
A Phase 3, multicenter, double-blind, randomized, placebo-controlled, parallel-group trial evaluating the efficacy, safety, and tolerability of cenerimod in combination with background therapy in adult patients with systemic lupus erythematosus and active lupus nephritis.

  • Condition/Disease

    Nephritis and nephropathy not specified as acute or chronic, classified elsewhere | Systemic lupus erythematosus

  • Test Drug

    Cenerimod

Participate Sites
9Sites

Not yet recruiting9Sites

2019-07-19 - 2022-01-01

Phase II

Completed
A Phase 2 Study to Investigate the Safety and Efficacy of ABBV-105 and Upadacitinib Given Alone or in Combination (ABBV-599 Combination) in Subjects with Moderately to Severely Active Systemic Lupus Erythematosus

  • Condition/Disease

    Systemic Lupus Erythematosus (SLE)

  • Test Drug

    NA

Participate Sites
6Sites

Recruiting6Sites

2024-10-01 - 2027-12-31

Phase II

Active
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Obexelimab in Patients with Systemic Lupus Erythematosus

  • Condition/Disease

    Systemic Lupus Erythematosus

  • Test Drug

    OBEXELIMAB (ZB012; XmAb5871)

Participate Sites
6Sites

Not yet recruiting5Sites

Recruiting1Sites

2026-03-01 - 2029-01-25

Phase III

Not yet recruiting
A Master Protocol for Phase 3 Randomized, Double-Blind, Placebo-Controlled Studies to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Osteoarthritis Knee Pain, and Obesity or Overweight (ENLIGHTEN-4)

  • Condition/Disease

    Osteoarthritis 、Overweight or Obesity

  • Test Drug

    預充填式注射劑 預充填式注射劑

Participate Sites
7Sites

Recruiting7Sites

2024-07-01 - 2026-04-20

Phase II

Completed
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Not yet recruiting1Sites

Recruiting4Sites

2023-06-16 - 2026-07-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Not yet recruiting1Sites

Terminated8Sites

2018-06-30 - 2022-06-30

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated4Sites

2021-10-29 - 2025-07-07

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Not yet recruiting1Sites

Recruiting2Sites

Terminated1Sites

2025-05-01 - 2026-01-30

Others

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2020-07-31 - 2024-02-06

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting3Sites

Recruiting2Sites

Terminated1Sites

1 2 3
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB